Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.08 (market cap $39.89B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.81. The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FLRN | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $30.86 |
52-Week Low | $278.09 | $30.65 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.80, showing minimal daily movement. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights institutional buying interest amid a rising rate environment, positioning FLRN as a potential hedge against inflation. The ETF pays consistent dividends, with recent distributions of $0.11 per share.
FLRN's outlook is shaped by its role in a higher-for-longer rate climate, offering floating-rate bond exposure that may outperform traditional fixed-income ETFs. Key risks include interest rate volatility and inflation trends. Institutional accumulation signals confidence, but the bearish technical trend warrants caution for near-term price action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
